৳ 7.50/unit
Pack: ৳ 75
৳ 7.50/unit
Pack: ৳ 75
At a glance
Venetoclax is indicated in combination with Rituximab for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
Indications
- Chronic lymphocytic leukemia (CLL)
Pharmacology
Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2. Overexpression of BCL-2 has been demonstrated in CLL cells where it mediates tumor cell survival and has been associated with resistance to chemotherapeutics.
Dosage
Adult Dose (Oral):
- Starting dose: 20 mg once daily for 7 days
- Gradually increased over 5 weeks up to 400 mg daily
- Post-titration dose in combination with Rituximab: 400 mg once daily; Rituximab started after 400 mg Venetoclax for 7 days
- Post-titration dose for monotherapy: 400 mg once daily; continue until disease progression or no longer tolerated
Side effects
Common Side Effects:
- Neutropenia
- Diarrhea
- Upper respiratory tract infection
- Nausea
- Anemia
- Fatigue
Use in pregnancy
Use in Pregnancy: Animal studies show embryo-fetal toxicity; not recommended during pregnancy; use effective contraception.
Pregnancy Category: D — always consult a doctor before taking during pregnancy.
Precautions & warnings
- Tumour lysis syndrome (TLS) can occur; prophylaxis with hydration and anti-hyperuricemics needed
- Monitor blood chemistries
- Monitor CBC for neutropenia
- Do not administer live vaccines
- Avoid CYP3A inhibitors and inducers
Overdose effects
Symptoms: TLS (fever, chills, nausea, vomiting, confusion, shortness of breath, seizures, irregular heartbeat, dark or cloudy urine, unusual tiredness, muscle or joint pain, abdominal pain and distension).
Treatment: No specific antidote; monitor closely and provide supportive treatment.
Storage conditions
Store below 30°C. Keep out of the sight and reach of children. Protect from moisture and light.